Ambroxol solution

2814USD

Description

Features

Reviews

Instructions for Ambroxol solution

English Product Name
Ambroxol

Release Form
syrup 15 mg/5 ml: fl. 50 ml or 100 ml

Description Ambroxol

Syrup 5 ml
ambroxol hydrochloride 15 mg
50 ml - dark glass bottles (1) complete with a measuring cup or spoon - packs of cardboard.
100 ml - dark glass bottles (1) complete with a measuring cup or spoon - packs of cardboard.

ATX codes

R05CB06 Ambroxol

Clinical and pharmacological groups / Group affiliation
Mucolytic and expectorant

Active ingredient
ambroxol hydrochloride

Pharmacotherapeutic group

Mucolytic agent

Pharmacological effect Ambroxol

A mucolytic and expectorant, it is an active N-demethylated metabolite of bromohexin. It has secretomotor, secretolytic and expectorant effects. Stimulates bronchial mucosal serous cells, increases the motor activity of the atrial epithelium by targeting type 2 pneumocytes in the alveoli and Clara cells in the bronchioles, and endogenous surfactant, a surfactant-surfactant that glides bronchial secretions through the airways.

Ambroxol increases the serous component’s share of the bronchial secretion, improving its structure and promoting viscosity reduction and sputum dilution; as a result, mucociliary transport is improved and sputum excretion from the bronchial tree is facilitated.

When ambroxol is taken by mouth, response usually occurs within 30 minutes and lasts 6 to 12 hours, depending on the dose given once.

Testimony Ambroxol

For administration by mouth
Respiratory tract disorders with excretion of viscous sputum and phlegm withdrawal:
acute and chronic bronchitis;
pneumonia;
asthma;
bronchiectasis;
COPD.

For In/Out

Respiratory tract diseases with excretion of viscous sputum and with difficulty of withdrawal of sputum in cases when it is necessary to obtain a rapid therapeutic effect or the drug cannot be taken by mouth: acute and chronic bronchitis; pneumonia; bronchial asthma; bronchiectasis; stimulation of surfactant synthesis in respiratory distress syndrome of premature infants and newborns (as part of complex therapy).

Method of use, course and dosage

The duration of treatment is determined by the doctor individually and depends on the severity of the disease. If the use of the drug more than four to five days requires consultation with a doctor.
For oral dosing, the dose is adjusted individually depending on the patient’s age and the dosage form used.